{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:23:06Z","timestamp":1740144186945,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T00:00:00Z","timestamp":1537747200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["14\/25"],"award-info":[{"award-number":["14\/25"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s40273-018-0713-7","type":"journal-article","created":{"date-parts":[[2018,9,23]],"date-time":"2018-09-23T21:32:41Z","timestamp":1537738361000},"page":"333-343","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6612-2332","authenticated-orcid":false,"given":"Paul","family":"Tappenden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Clowes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Kaltenthaler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Meiklejohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Morley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,24]]},"reference":[{"key":"713_CR1","unstructured":"National Institute for Health and Care Excellence. Guide to the processes of technology appraisal. London: NICE; 2014. https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/foreword . Accessed 01 Apr 2018."},{"key":"713_CR2","unstructured":"Tappenden P, Simpson E, Sanderson J, Pollard D, Clowes M, Kaltenthaler E, et al. Ibrutinib for treating relapsed or refractory mantle cell lymphoma: a single technology appraisal. Sheffield: University of Sheffield; 2016. https:\/\/www.nice.org.uk\/guidance\/ta502\/documents\/committee-papers . Accessed 04 Mar 2018."},{"key":"713_CR3","unstructured":"National Institute for Health and Care Excellence. Ibrutinib for treating relapsed or refractory mantle cell lymphoma: final appraisal determination. London: NICE; 2017. https:\/\/www.nice.org.uk\/guidance\/ta502\/documents\/final-appraisal-determination-document . Accessed 01 May 2018."},{"key":"713_CR4","unstructured":"National Institute for Health and Care Excellence. Ibrutinib for treating relapsed or refractory mantle cell lymphoma: technology appraisal guidance. London: NICE; 2017. https:\/\/www.nice.org.uk\/guidance\/ta502 . Accessed 01 May 2018."},{"key":"713_CR5","unstructured":"National Institute for Health and Care Excellence. Ibrutinib for treating relapsed or refractory mantle cell lymphoma. London: NICE; 2017. https:\/\/www.nice.org.uk\/guidance\/ta502 . Accessed 01 June 2018."},{"key":"713_CR6","unstructured":"Janssen Ltd. Ibrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Company\u2019s evidence submission to the National Institute for Health and Care Excellence. High Wycombe: Janssen; 2016. https:\/\/www.nice.org.uk\/guidance\/ta502\/documents\/committee-papers . Accessed 04 Mar 2018."},{"key":"713_CR7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/bjh.12046","volume":"159","author":"P McKay","year":"2012","unstructured":"McKay P, Leach M, Jackson R, Cook G, Rule S. Guidelines for the investigation and management of mantle cell lymphoma. Br J Haematol. 2012;159:405\u201326.","journal-title":"Br J Haematol"},{"issue":"4","key":"713_CR8","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/annonc\/mds643","volume":"24","author":"M Dreyling","year":"2013","unstructured":"Dreyling M, Thieblemont C, Gallamini A, Arcaini L, Campo E, Hermine O, et al. ESMO consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol. 2013;24(4):857\u201377.","journal-title":"Ann Oncol"},{"key":"713_CR9","unstructured":"National Institute for Health and Care Excellence. Ibrutinib for treating relapsed or refractory mantle cell lymphoma: final scope. London: NICE; 2016. https:\/\/www.nice.org.uk\/guidance\/ta502\/documents\/final-scope . Accessed 01 Apr 2018."},{"key":"713_CR10","unstructured":"Janssen Ltd. Ibrutinib for treating mantle cell lymphoma. Company\u2019s response to clarification questions from the ERG. High Wycombe: Janssen; 2016. https:\/\/www.nice.org.uk\/guidance\/ta502\/documents\/committee-papers . Accessed 04 Mar 2018."},{"issue":"10020","key":"713_CR11","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","volume":"387","author":"M Dreyling","year":"2016","unstructured":"Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387(10020):770\u20138.","journal-title":"Lancet"},{"issue":"6","key":"713_CR12","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507\u201316.","journal-title":"N Engl J Med"},{"key":"713_CR13","unstructured":"Wang M, Goy A, Martin P, Ramchandran R, Alexeeva J, Popat R. Efficacy and safety of single-agent ibrutinib in patients with mantle cell lymphoma who progressed after bortezomib therapy. In: 56th American Society of Hematology (ASH) annual meeting and exposition, San Francisco, 6\u20139 Dec 2014."},{"issue":"23","key":"713_CR14","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","volume":"27","author":"G Hess","year":"2009","unstructured":"Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, et al. Phase III study to evaluate temsirolimus compared with investigator\u2019s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27(23):3822\u20139.","journal-title":"J Clin Oncol"},{"key":"713_CR15","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1182\/blood.V112.11.828.828","volume":"112","author":"GC Carter","year":"2008","unstructured":"Carter GC, Liepa A, Zimmerman AH, Morschhauser F. Validation of the Functional Assessment of Therapy\u2014Lymphoma (FACT-LYM) in patients with relapsed\/refractory mantle cell lymphoma. (Abstract 2376). Blood. 2008;112:828.","journal-title":"Blood"},{"issue":"10","key":"713_CR16","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"R Forstpointner","year":"2004","unstructured":"Forstpointner R, Dreyling M, Repp R, Hermann S, H\u00e4nel A, Metzner B, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004;104(10):3054\u201371.","journal-title":"Blood"},{"key":"713_CR17","volume-title":"Clinical management and outcome in mantle cell lymphoma\u2014version 1.4","author":"Haematological Malignancy Research Network","year":"2016","unstructured":"Haematological Malignancy Research Network. Clinical management and outcome in mantle cell lymphoma\u2014version 1.4. York: HMRN; 2016."},{"key":"713_CR18","unstructured":"Janssen Research and Development. Data on File\u2014Imbruvica (ibrutinib)\u2014pooled analysis [data held on file]. High Wycombe: Janssen; 2016."},{"key":"713_CR19","volume-title":"RAY (MCL3001) Clinical Study Report","author":"Janssen Research and Development","year":"2015","unstructured":"Janssen Research and Development. RAY (MCL3001) Clinical Study Report. High Wycombe: Janssen; 2015."},{"key":"713_CR20","volume-title":"SPARK (MCL2001) Clinical Study Report","author":"Janssen Research and Development","year":"2014","unstructured":"Janssen Research and Development. SPARK (MCL2001) Clinical Study Report. High Wycombe: Janssen; 2014."},{"key":"713_CR21","unstructured":"Haymarket Media Group. Monthly Index of Medical Specialties (MIMS); 2016. https:\/\/www.mims.co.uk\/ . Accessed 2 Jan 2016."},{"key":"713_CR22","unstructured":"Commercial Medicines Unit. Drugs and pharmaceutical electronic market information (eMit). https:\/\/www.gov.uk\/government\/publications\/drugs-and-pharmaceutical-electronic-market-information-emit2015 . Accessed 20 Mar 2016."},{"key":"713_CR23","unstructured":"Department of Health. Reference Costs 2014\/15. London: DH; 2015. https:\/\/www.gov.uk\/government\/publications\/nhs-reference-costs-2014-to-2015 . Accessed 01 May 2016."},{"issue":"7","key":"713_CR24","doi-asserted-by":"publisher","first-page":"A620","DOI":"10.1016\/j.jval.2014.08.2196","volume":"17","author":"S Peng","year":"2014","unstructured":"Peng S, Sorensen S, Pan F, Dorman E, Sun S, Van Sanden S, et al. Simulation model of ibrutinib in treatment of relapsed or refractory mantle cell lymphoma (MCL). Value Health. 2014;17(7):A620.","journal-title":"Value Health"},{"key":"713_CR25","unstructured":"National Institute for Health and Care Excellence. Ibrutinib for treating relapsed or refractory mantle cell lymphoma: appraisal consultation document. London: NICE; 2016. https:\/\/www.nice.org.uk\/guidance\/ta502\/documents\/appraisal-consultation-document . Accessed 01 May 2018."},{"key":"713_CR26","doi-asserted-by":"publisher","first-page":"A141","DOI":"10.1016\/j.jval.2013.03.690","volume":"12","author":"J Lachaine","year":"2013","unstructured":"Lachaine J, Beauchemin C, Mathurin K, Aissa F. Cost-effectiveness of bendamustine + rituximab versus fludarabine + rituximab in the treatment of relapsed indolent non-Hodgkin\u2019s and mantle cell lymphomas in Canada. Value Health. 2013;12:A141.","journal-title":"Value Health"},{"key":"713_CR27","doi-asserted-by":"publisher","first-page":"A273","DOI":"10.1016\/S1098-3015(10)74336-9","volume":"12","author":"K Yoong","year":"2009","unstructured":"Yoong K, Attard C, Jivraj F, Sehn L. Cost-effectiveness analysis of bortezomib in relapsed mantle cell lymphoma patients in Canada. Value Health. 2009;12:A273.","journal-title":"Value Health"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-018-0713-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-018-0713-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-018-0713-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T13:40:26Z","timestamp":1571924426000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-018-0713-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,24]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["713"],"URL":"https:\/\/doi.org\/10.1007\/s40273-018-0713-7","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"type":"print","value":"1170-7690"},{"type":"electronic","value":"1179-2027"}],"subject":[],"published":{"date-parts":[[2018,9,24]]},"assertion":[{"value":"24 September 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (Project No. 14\/177\/09). See the HTA programme website for further project information (). This summary of the ERG report was compiled after NICE issued the FAD. The views expressed in this report are those of the authors and not necessarily those of the NIHR HTA Programme. Any errors are the responsibility of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Paul Tappenden, Emma Simpson, Jean Hamilton, Daniel Pollard, Mark Clowes, Eva Kaltenthaler, David Meiklejohn and Nick Morley have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}